Jim Simons Enanta Pharmaceuticals Inc Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 524,900 shares of ENTA stock, worth $3.34 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

524,900

Previous 510,900 2.74%

Holding current value

$3.34 Million

Previous $6.63 Million 17.85%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$10.05 - $16.54 $140,700 - $231,560	14,000 Added 2.74%	524,900 $5.44 Million
Q2 2024 Aug 09, 2024	SELL	$11.43 - $17.02 $173,736 - $258,704	-15,200 Reduced 2.89%	510,900 $6.63 Million
Q1 2024 May 13, 2024	SELL	$10.08 - $17.46 $326,592 - $565,704	-32,400 Reduced 5.8%	526,100 $9.19 Million
Q4 2023 Feb 13, 2024	BUY	$8.18 - $10.78 $821,272 - $1.08 Million	100,400 Added 21.92%	558,500 $5.26 Million
Q3 2023 Nov 14, 2023	SELL	$11.09 - $22.13 $201,838 - $402,766	-18,200 Reduced 3.82%	458,100 $5.12 Million
Q2 2023 Aug 11, 2023	BUY	$20.68 - $39.85 $1.01 Million - $1.95 Million	48,836 Added 11.42%	476,300 $10.2 Million
Q1 2023 May 12, 2023	SELL	$38.82 - $54.59 $1.78 Million - $2.5 Million	-45,736 Reduced 9.67%	427,464 $17.3 Million
Q4 2022 Feb 13, 2023	BUY	$40.77 - $53.73 $212,004 - $279,396	5,200 Added 1.11%	473,200 $22 Million
Q3 2022 Nov 14, 2022	SELL	$48.29 - $71.27 $3.61 Million - $5.33 Million	-74,800 Reduced 13.78%	468,000 $24.3 Million
Q2 2022 Aug 12, 2022	SELL	$38.13 - $76.93 $2.45 Million - $4.95 Million	-64,300 Reduced 10.59%	542,800 $25.7 Million
Q1 2022 May 13, 2022	SELL	$56.06 - $74.11 $6.02 Million - $7.95 Million	-107,300 Reduced 15.02%	607,100 $43.2 Million
Q4 2021 Feb 11, 2022	SELL	$60.19 - $97.37 $2.54 Million - $4.11 Million	-42,185 Reduced 5.58%	714,400 $53.4 Million
Q3 2021 Nov 12, 2021	SELL	$41.02 - $58.65 $1.69 Million - $2.41 Million	-41,143 Reduced 5.16%	756,585 $43 Million
Q2 2021 Aug 13, 2021	SELL	$43.76 - $53.11 $4.48 Million - $5.44 Million	-102,472 Reduced 11.38%	797,728 $35.1 Million
Q1 2021 May 13, 2021	SELL	$41.69 - $54.95 $5.57 Million - $7.35 Million	-133,700 Reduced 12.93%	900,200 $44.4 Million
Q4 2020 Feb 10, 2021	BUY	$41.16 - $47.47 $201,683 - $232,603	4,900 Added 0.48%	1,033,900 $43.5 Million
Q3 2020 Nov 13, 2020	BUY	$43.36 - $53.53 $3.73 Million - $4.61 Million	86,100 Added 9.13%	1,029,000 $47.1 Million
Q2 2020 Aug 13, 2020	BUY	$46.37 - $57.58 $2.89 Million - $3.59 Million	62,300 Added 7.07%	942,900 $47.3 Million
Q1 2020 May 14, 2020	BUY	$40.22 - $62.0 $5.99 Million - $9.24 Million	149,000 Added 20.37%	880,600 $45.3 Million
Q4 2019 Feb 13, 2020	BUY	$57.95 - $66.61 $3.98 Million - $4.58 Million	68,700 Added 10.36%	731,600 $45.2 Million
Q3 2019 Nov 13, 2019	BUY	$60.08 - $88.17 $6.77 Million - $9.93 Million	112,600 Added 20.46%	662,900 $39.8 Million
Q2 2019 Aug 12, 2019	SELL	$81.3 - $97.35 $7.74 Million - $9.27 Million	-95,205 Reduced 14.75%	550,300 $46.4 Million
Q1 2019 May 14, 2019	SELL	$69.08 - $105.66 $10.5 Million - $16 Million	-151,695 Reduced 19.03%	645,505 $61.7 Million
Q4 2018 Feb 13, 2019	BUY	$65.41 - $84.65 $52.1 Million - $67.5 Million	797,200 New	797,200 $56.5 Million

Others Institutions Holding ENTA

# of Institutions

110

Shares Held

21.1M

Call Options Held

4.8K

Put Options Held

4.6K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $132M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account